Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The firm also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. The company provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.
Follow-Up Questions
Spectral Medical Inc의 CEO는 누구입니까?
Mr. Chris Seto은 2019부터 회사에 합류한 Spectral Medical Inc의 Chief Executive Officer입니다.
EDTXF 주식의 가격 성능은 어떻습니까?
EDTXF의 현재 가격은 $1.09이며, 전 거래일에 decreased 0% 하였습니다.
Spectral Medical Inc의 주요 사업 주제나 업종은 무엇입니까?
Spectral Medical Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Spectral Medical Inc의 시가총액은 얼마입니까?
Spectral Medical Inc의 현재 시가총액은 $315.2M입니다
Spectral Medical Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Spectral Medical Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 2명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
